NCT04688671CompletedPhase 2
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects With Diabetic Peripheral Neuropathic Pain
Eliem Therapeutics (UK) Ltd.22 sites in 1 country167 target enrollmentStarted: November 9, 2020Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Eliem Therapeutics (UK) Ltd.
- Enrollment
- 167
- Locations
- 22
- Primary Endpoint
- Change From Baseline to Week 4 in the Weekly Average of the Daily Pain Score as Derived From the Subject's Responses on the Pain Intensity Numerical Rating Scale (PI-NRS)
Study Overview
Brief Summary
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects with Diabetic Peripheral Neuropathic Pain.
Detailed Description
ETX-018810 is a new chemical entity that is under development as a non-opioid treatment for chronic pain syndromes. ETX-018810 is a prodrug of palmitoylethanolamide (PEA), an endogenous bioactive lipid that has shown efficacy in a broad range of nonclinical inflammatory and neuropathic pain models and in clinical trials in chronic pain indications, including diabetic peripheral neuropathic pain (DPNP).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Masking Description
Double-Blind
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •The subject is ≥18 and ≤75 years of age at the time of signing ICF.
- •The subject has a diagnosis of type 1 or 2 diabetes mellitus.
- •The subject has diabetic neuropathy of a symmetrical nature in the lower extremities for ≥6 months to ≤10 years
- •The subject reports at least moderate pain intensity
- •The subject's onset of neuropathic pain is at least 3 months before the screening visit.
- •The subject has used a stable regimen of antidiabetic agents for at least 1 month before the baseline visit or has achieved adequate glycemic control through diet and exercise.
- •The subject has clinical laboratory values within normal limits or abnormal values that the investigator deems not clinically significant.
- •Sexually active male subjects with female partners of childbearing potential and sexually active female subjects of childbearing potential must agree to practice effective contraception or to remain abstinent during the study and for 4 weeks after the last dose of investigational product
- •The subject is capable of giving signed informed consent and agrees to provide authorization for use and release of health records.
Exclusion Criteria
- •The subject has pain that cannot be clearly differentiated from or that could interfere with the assessment of DPNP.
- •The subject has neurologic and/or circulatory disorders that are unrelated to diabetic neuropathy
- •The subject has a history of hypoglycemia that disturbed consciousness or ketoacidosis that required hospitalization within the 3 months before screening.
- •The subject has clinically significant and/or unstable renal, hepatic, hematologic, immunologic, inflammatory/rheumatologic, respiratory, or cardiovascular disease that would compromise participation in the study in the judgment of the investigator.
- •The subject has any neurological disease that could interfere with participation in the study (eg, Huntington's disease, Parkinson's disease, Alzheimer's disease, multiple sclerosis, seizures, epilepsy, stroke).
- •The subject has an amputation of a lower extremity. Toe amputation is allowed.
- •The subject has clinically significant abnormal electrocardiogram (ECG) findings at screening or baseline.
- •The subject is likely to require major surgery during the study.
- •The subject is pregnant or lactating.
- •The subject is unwilling or unable to discontinue current medications for neuropathic pain, including topical agents.
- •The subject is unable to refrain from using nonsteroidal anti-inflammatory drugs (NSAIDs); antiepileptic drugs, steroids, cannabinoids, or major opioids, muscle relaxants, tramadol, or tapentadol throughout the study.
- •The subject has used prohibited nonpharmacologic therapies, including acupuncture, transcutaneous electrical nerve stimulation, etc, within 30 days before baseline/Day 1 or anticipates use of such therapies during the study.
Arms & Interventions
ETX-018810
Experimental
1000 mg BID for 4 weeks
Intervention: ETX-018810 (Drug)
Placebo
Placebo Comparator
matching placebo BID for 4 weeks
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Change From Baseline to Week 4 in the Weekly Average of the Daily Pain Score as Derived From the Subject's Responses on the Pain Intensity Numerical Rating Scale (PI-NRS)
Time Frame: baseline to Week 4
Change from baseline in the weekly average of the daily pain score as derived from the subject's responses on the Pain Intensity Numerical Rating Scale (PI-NRS) a 10 point scale from 0 being the least (No Pain) to 10 being the most (Worst Possible Pain).
Secondary Outcomes
- Change in the BPI - Interference Scale From Baseline to Week 4(Baseline to Week 4)
- Number of Subjects With a CGI-C Response (Defined as "Much Improved" or "Very Much Improved") at Week 4(Week 4)
- Change in the BPI-Pain Scale From Baseline to Week 4(Baseline to Week 4)
- Number of Subjects With a ≥50% Reduction From Baseline to Weeks 1, 2, 3, and 4 in the Weekly Average of the Daily Pain Score(Baseline to Weeks 1, 2, 3 and 4)
- Number of Subjects With a ≥30% Reduction From Baseline to Weeks 1, 2, 3, and 4 in the Weekly Average of the Daily Pain Score(Baseline to Weeks 1, 2, 3 and 4)
- Change in the Weekly Average of the Daily Sleep Score on the DSIS From Baseline to Weeks 1, 2, 3, and 4(Baseline to Weeks 1, 2, 3 and 4)
- Change in the Weekly Average of the Daily Pain Score From Baseline to Weeks 1, 2, and 3(Baseline to Weeks 1, 2 and 3)
- Number of Subjects With a PGI-C Response (Defined as "Much Improved" or "Very Much Improved") at Week 4.(Week 4)
- Change in the Daily Amount of Acetaminophen Use From Baseline to Week 4(Baseline to week 4)
Investigators
Study Sites (22)
Loading locations...
Similar Trials
Completed
Phase 2
Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Moderate to Severe ConjunctivochalasisConjunctivochalasisNCT02804191Ocuwize LTD62
Completed
Phase 2
A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)Non-Alcoholic Fatty Liver DiseaseNCT03350165Kowa Company, Ltd.118
Completed
Phase 3
Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.AsthmaNCT01498679GlaxoSmithKline311
Unknown
Phase 1
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI MalignanciesCancer of PancreasCancer of LiverCancer of RectumCancer of ColonCancer, Gall BladderMyeloma MultipleGlioblastoma MultiformeNCT03607643Leaf Vertical Inc.160
Completed
Phase 3
Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma ControlAsthmaNCT02281318GlaxoSmithKline556